Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial - Poll - MDSpire

Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial

  • By

  • Bart L Clarke

  • Aliya A Khan

  • Mishaela R Rubin

  • Peter Schwarz

  • Tamara Vokes

  • Dolores M Shoback

  • Claudia Gagnon

  • Andrea Palermo

  • Lisa G Abbott

  • Lorenz C Hofbauer

  • Lynn Kohlmeier

  • Filomena Cetani

  • Susanne Pihl

  • Xuebei An

  • Alden R Smith

  • Bryant Lai

  • Jenny Ukena

  • Christopher T Sibley

  • Aimee D Shu

  • Lars Rejnmark

  • October 8, 2024

  • 0 min

Share

Original Source(s)

Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial

  • by Bart L Clarke, Aliya A Khan, Mishaela R Rubin, Peter Schwarz, Tamara Vokes, Dolores M Shoback, Claudia Gagnon, Andrea Palermo, Lisa G Abbott, Lorenz C Hofbauer, Lynn Kohlmeier, Filomena Cetani, Susanne Pihl, Xuebei An, Alden R Smith, Bryant Lai, Jenny Ukena, Christopher T Sibley, Aimee D Shu, Lars Rejnmark

  • October 8, 2024

Related Content

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

Ultrasound Models Estimate Whole-Body Muscle Mass

New equations incorporating cross-sectional area improve estimation accuracy.

Body Composition by DXA in Patients with Klinefelter and Kallmann Syndrome: The Kama Study